fluticasone propionate/formoterol fumarate metered dose inhaler 50 microgram/5 microgram (flutiform®)

Napp Pharmaceuticals Ltd

10 May 2019

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

fluticasone propionate/formoterol fumarate (flutiform®) is accepted for use within NHSScotland.

Indication under review: the regular treatment of asthma in children aged 5 to 12 years where the use of a combination product (an inhaled corticosteroid and a long-acting β2 agonist) is appropriate:
• For patients not adequately controlled with inhaled corticosteroids and 'as required' inhaled short-acting β2 agonist.
Or
• For patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist.

SMC has previously accepted fluticasone propionate/formoterol fumarate for use in adults and adolescents aged 12 years and above with asthma where the use of a combination product is appropriate.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their
clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 05 March 2019.

Chairman
Scottish Medicines Consortium